journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://www.readbyqxmd.com/read/28870636/de-novo-erbb2-amplification-causing-intrinsic-resistance-to-erlotinib-in-egfr-l858r-mutated-tki-na%C3%A3-ve-lung-adenocarcinoma
#1
LETTER
Brian J Carney, Deepa Rangachari, Paul A VanderLaan, Kyle Gowen, Alexa B Schrock, Siraj M Ali, Daniel B Costa
No abstract text is available yet for this article.
August 24, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28916198/treatment-outcome-and-quality-of-life-of-1239-patients-with-advanced-non-small-cell-lung-cancer-final-results-from-the-prospective-german-tlk-cohort-study
#2
Ulla von Verschuer, Roland Schnell, Hans Werner Tessen, Jochen Eggert, Adrian Binninger, Lisa Spring, Martina Jänicke, Norbert Marschner
OBJECTIVES: Real-life data on advanced non-small cell lung cancer (NSCLC) are centrally important to complement the results from clinical trials and to improve the standard of care. We present data on the choice of systemic first- and second-line treatment, number of treatment lines, survival and longitudinal data on health-related quality of life (HRQOL) of patients treated by medical oncologists in Germany. MATERIALS AND METHODS: 1239 patients with advanced NSCLC were recruited at start of first-line therapy into the prospective German clinical cohort study TLK (Tumour Registry Lung Cancer) by 107 sites between February 2010 and December 2013 and followed-up until January 2016...
August 22, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28826675/corrigendum-to-gender-difference-in-human-papillomarvirus-infection-for-non-small-cell-lung-cancer-in-taiwan-lung-cancer-46-november-2-2004-165-170
#3
Ya-Wen Cheng, Hui-Ling Chiou, Jung-Ta Chen, Ming-Chih Chou, Torng-Sen Lin, Wu-Wei Lai, Chih-Yi Chen, Yi-Yu Tsai, Huei Lee
No abstract text is available yet for this article.
August 18, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28847520/do-we-understage-sabr-candidates
#4
EDITORIAL
Laurence M M J Crombag, Jouke T Annema
No abstract text is available yet for this article.
August 9, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28780994/cardiogenic-shock-in-a-patient-being-treated-with-atezolizumab-for-metastatic-non-small-cell-lung-cancer
#5
LETTER
Ellen Liu, Avirup Guha, Erin Bertino, Veronica Franco
No abstract text is available yet for this article.
July 29, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28757047/need-for-randomized-clinical-trials-testing-targeted-therapies-in-malignant-pleural-mesothelioma
#6
LETTER
N Sobhani, G Roviello, S P Corona, A Ianza, F Zanconati, D Generali
No abstract text is available yet for this article.
July 24, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28754417/marked-response-to-pembrolizumab-in-a-patient-with-pulmonary-pleomorphic-carcinoma-highly-positive-for-pd-l1
#7
LETTER
Yuki Ikematsu, Yasuto Yoneshima, Kayo Ijichi, Kentaro Tanaka, Taishi Harada, Yoshinao Oda, Yoichi Nakanishi, Isamu Okamoto
No abstract text is available yet for this article.
July 21, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28800837/outcomes-of-invasive-mediastinal-nodal-staging-versus-positron-emission-tomography-staging-alone-for-early-stage-non-small-cell-lung-cancer-treated-with-stereotactic-body-radiation-therapy
#8
Caitlin A Schonewolf, Vivek Verma, Carl M Post, Abigail T Berman, Melissa A Frick, Anil Vachani, Chi Lin, Charles B Simone
BACKGROUND: The benefit of invasive mediastinal nodal staging (IMNS) in addition to positron emission tomography-computed tomography (PET/CT) is undefined for early stage non-small cell lung cancer (NSCLC). This multi-institutional investigation aimed to evaluate outcomes and patterns of failure in patients staged with PET/CT with or without additional IMNS. METHODS: Two academic centers assessed all consecutive patients staged with PET/CT for early-stage, primary lung NSCLC (cT1-2aN0M0) treated with SBRT...
July 14, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28733075/the-establishing-of-a-new-thoracic-surgery-department-in-greece-in-the-era-of-financial-crisis
#9
LETTER
Emmanouil I Kapetanakis, Tatiana Sidiropoulou, Anastasios Machairas, Periklis Tomos
No abstract text is available yet for this article.
July 12, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28709627/plasma-concentration-of-osimertinib-in-a-non-small-cell-lung-cancer-patient-with-chronic-renal-failure-undergoing-hemodialysis
#10
LETTER
Tomohiro Tamura, Yuki Takagi, Hatsumi Okubo, Shozaburo Yamaguchi, Yasuko Kikkawa, Ikuta Hashimoto, Takayuki Kaburagi, Masatomo Miura, Hiroaki Satoh, Nobuyuki Hizawa
No abstract text is available yet for this article.
July 8, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28838407/lung-cancer-in-renal-transplant-recipients-a-case-control-study
#11
Claire Rousseau-Gazaniol, Séverine Fraboulet, Louis-Jean Couderc, Henri Kreis, Raphaël Borie, Leila Tricot, Dany Anglicheau, Frank Martinez, Hélène Doubre, Pierre Bonnette, François Mellot, Marie-Ange Massiani, Gaëlle Pelle, Edouard Sage, Patricia Moisson, Michel Delahousse, Leila Zemoura, Alain Chapelier, Abdul Monem Hamid, Philippe Puyo, Elisabeth Longchampt, Christophe Legendre, Sylvie Friard, Emilie Catherinot
INTRODUCTION: Solid organ transplant patients are at heightened risk of several cancers compared to the general population. Secondary to a higher number of procedures and better survival after transplantation, cancer is a rising health concern in this situation. Limited data exist for lung cancer (LC) after renal transplantation. We report here the most important series of renal transplant recipients with lung cancer. METHODS: Retrospective study of all cases of LC diagnosed in three French Renal Transplant Units from 2003 to 2012...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28838406/clinical-significance-of-preoperative-serum-albumin-level-for-prognosis-in-surgically-resected-patients-with-non-small-cell-lung-cancer-comparative-study-of-normal-lung-emphysema-and-pulmonary-fibrosis
#12
Kentaro Miura, Kazutoshi Hamanaka, Tomonobu Koizumi, Yoshiaki Kitaguchi, Yukihiro Terada, Daisuke Nakamura, Hirotaka Kumeda, Hiroyuki Agatsuma, Akira Hyogotani, Satoshi Kawakami, Akihiko Yoshizawa, Shiho Asaka, Ken-Ichi Ito
OBJECTIVES: This study was performed to clarify whether preoperative serum albumin level is related to the prognosis of non-small cell lung cancer patients undergoing surgical resection, and the relationships between serum albumin level and clinicopathological characteristics of lung cancer patients with emphysema or pulmonary fibrosis. MATERIALS AND METHODS: We retrospectively evaluated 556 patients that underwent surgical resection for non-small cell lung cancer...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28838405/emergence-of-egfr-g724s-mutation-in-egfr-mutant-lung-adenocarcinoma-post-progression-on-osimertinib
#13
A Oztan, S Fischer, A B Schrock, R L Erlich, C M Lovly, P J Stephens, J S Ross, V Miller, S M Ali, S-H I Ou, L E Raez
Mutations in the epidermal growth factor receptor (EGFR) are drivers for a subset of lung cancers. Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) recently approved for the treatment of T790M-positive non-small cell lung cancer (NSCLC); however, acquired resistance to osimertinib is evident and resistance mechanisms remain incompletely defined. The EGFR G724S mutation was detected using hybrid-capture based comprehensive genomic profiling (CGP) and a hybrid-capture based circulating tumor DNA (ctDNA) assays in two cases of EGFR-driven lung adenocarcinoma in patients who had progressed on osimertinib treatment...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28838404/validation-of-alk-ros1-dual-break-apart-fish-probe-probe-in-non-small-cell-lung-cancer
#14
Sun Min Lim, Hyun Chang, Yoon Jin Cha, Shile Liang, Yan Chin Tai, Gu Li, Ekaterina Pestova, Frank Policht, Thomas Perez, Ross A Soo, Won Young Park, Hye Ryun Kim, Hyo Sup Shim, Byoung Chul Cho
BACKGROUND: ALK and ROS1 gene rearrangements are distinct molecular subsets of non-small-cell lung cancer (NSCLC), and they are strong predictive biomarkers of response to ALK/ROS1 inhibitors, such as crizotinib. Thus, it is clinically important to develop an effective screening strategy to detect patients who will benefit from such treatment. In this study, we aimed to validate analytical performance of Vysis ALK/ROS1 Dual Break Apart Probe Kit (RUO) in NSCLC. METHODS: Study population composed of three patient cohorts with histologically confirmed lung adenocarcinoma (patients with ALK rearrangement, patients with ROS1 rearrangement and patients with wild-type ALK and ROS1)...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28838403/pathological-complete-response-in-malignant-pleural-mesothelioma-patients-following-induction-chemotherapy-predictive-factors-and-outcomes
#15
Brandon Lau, Sanjeev Kumar, Tristan Yan, Juliet Burn, Catherine Kennedy, Jocelyn McLean, Michael Boyer, Brian McCaughan, Steven Kao
A small proportion of patients with malignant pleural mesothelioma (MPM) achieve pathological complete response (CR) following treatment with current practice induction chemotherapy. Our analysis of 58 patients with MPM treated with platinum-based chemotherapy showed 4 patients (7%) attained pathological CR at subsequent extrapleural pneumonectomy (EPP). Patient and tumour factors such as age, gender, smoking habit, histological subtype, and clinical stage were not found to be associated with pathological CR...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28838402/ipsilateral-pleural-recurrence-after-diagnostic-transthoracic-needle-biopsy-in-pathological-stage-i-lung-cancer-patients-who-underwent-curative-resection
#16
Seong Mi Moon, Dae Geun Lee, Na Young Hwang, Soohyun Ahn, Hyun Lee, Byeong-Ho Jeong, Yong Soo Choi, Young Mog Shim, Tae Jeong Kim, Kyung Soo Lee, Hojoong Kim, O Jung Kwon, Kyung Jong Lee
OBJECTIVES: The relationship between transthoracic needle biopsy (TTNB) and pleural recurrence of cancer after curative lung resection remains unclear. We aimed to assess whether TTNB increases the ipsilateral pleural recurrence (IPR) rate and identify other potential risk factors for pleural recurrence after surgery. MATERIALS AND METHODS: This retrospective study included 392 patients with p-stage I non-small cell lung cancer with solid or part-solid nodules after curative lung resection in 2009-2010...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28838401/lack-of-response-to-nivolumab-in-a-patient-with-egfr-mutant-non-small-cell-lung-cancer-adenocarcinoma-sub-type-transformed-to-small-cell-lung-cancer
#17
Nadza Tokaca, Andrew Wotherspoon, Andrew G Nicholson, Nicos Fotiadis, Lisa Thompson, Sanjay Popat
Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28838400/emergence-of-fgfr3-tacc3-fusions-as-a-potential-by-pass-resistance-mechanism-to-egfr-tyrosine-kinase-inhibitors-in-egfr-mutated-nsclc-patients
#18
Sai-Hong Ignatius Ou, Leora Horn, Marcelo Cruz, Davood Vafai, Christine M Lovly, Allison Spradlin, Michael J Williamson, Ibiayi Dagogo-Jack, Adrienne Johnson, Vincent A Miller, Shirish Gadgeel, Siraj M Ali, Alexa B Schrock
Resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancers (NSCLCs) with activating EGFR mutations generally involve development of acquired secondary or tertiary EGFR mutations, such as T790M or C797S. However, case reports have demonstrated that actionable receptor tyrosine kinase fusions such as EML4-ALK, CCDC6-RET, and FGFR3-TACC3 can potentially confer resistance to EGFR TKIs. We seeked to identify the prevalence of FGFR3-TACC3 fusion transcripts as resistance mechanism to EGFR TKIs...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28838399/phase-i-clinical-trials-in-patients-with-advanced-non-small-cell-lung-cancer-treated-within-a-drug-development-unit-what-have-we-learnt
#19
Marta Capelan, Desamparados Roda, Elena Geuna, Karim Rihawi, Shankar Bodla, Stan B Kaye, Jaishree Bhosle, Udai Banerji, Mary O'Brien, Johann S de Bono, Sanjay Popat, Timothy A Yap
OBJECTIVES: Despite advances in novel drug development for patients with advanced non-small cell lung cancer (NSCLC), there are still only a limited number of approved treatments. We therefore evaluated the clinical outcomes of patients with advanced NSCLC referred to a dedicated phase I clinical trials unit assessed baseline clinical factors associated with successful enrollment onto phase I trials. MATERIAL AND METHODS: We conducted a retrospective study involving patients with advanced NSCLC referred to the Drug Development Unit at the RMH between January 2005 and December 2013...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28838398/peritoneal-recurrence-of-thymoma-treated-by-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#20
Camille Mazza, Jordi Remon, Charles Honoré, Benjamin Besse
Thymomas are rare (1,5 cases/million) and typically occur in adults with a median age of 50 years old. Thymomas are indolent with a 10-year overall survival for resected stage II thymomas of 70%. Late relapses occur in 20% of the cases, and distant metastasis from thymoma is rare. Peritoneal recurrence of thymoma treated with surgery associated with hyperthermic intraperitoneal chemotherapy (HIPEC) has not been described in the literature. This report manages peritoneal recurrence of thymoma with HIPEC, suggesting that aggressive therapies may decrease the risk of recurrence...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"